Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada.
Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada.
Can J Cardiol. 2015 Jun;31(6):809-11. doi: 10.1016/j.cjca.2014.12.034. Epub 2015 Jan 10.
Thrombocytopenia in acute coronary syndromes (ACS) can arise from a variety of etiologies. Glycoprotein IIb/IIIa receptor antagonists have improved clinical outcomes in ACS, however, profound thrombocytopenia can occur with use of these agents. We present a case of profound thrombocytopenia due to administration of a glycoprotein IIb/IIIa receptor antagonist, eptifibatide, after percutaneous coronary intervention for an inferior ST-elevation myocardial infarction. We review the major causes and suggest an approach for diagnosis and management of thrombocytopenia in ACS.
急性冠脉综合征（ACS）中的血小板减少症可能由多种病因引起。糖蛋白 IIb/IIIa 受体拮抗剂可改善 ACS 的临床结局，但使用这些药物可导致严重的血小板减少症。我们报告了一例因经皮冠状动脉介入治疗下壁 ST 段抬高型心肌梗死而使用糖蛋白 IIb/IIIa 受体拮抗剂依替巴肽导致的严重血小板减少症。我们回顾了主要病因，并提出了 ACS 中血小板减少症的诊断和处理方法。
